Study of exosomes derived from activated platelets in multiple sclerosis relapse and remission paired patients
ECTRIMS Online Library. Varadé J. 279682; EP1540
Jezabel Varadé
Jezabel Varadé
Contributions
Abstract

Abstract: EP1540

Type:

Abstract Category: Pathology and pathogenesis of MS - Biomarkers

A. Piñeiro-Abuin1, I. González-Suarez2, M. Peleteiro3, C. Sánchez-Franco2, M. Aguado-Valcarcel2, E. Álvarez2, G. Pinzaru4, R. Lorenzo-Castro5, Á. González-Fernández1, J. Varadé1

1Immunology Research Group, Biomedical Research Centre (CINBIO), Vigo University, 2Multiple Sclerosis Unit, Neurology Department, Alvaro Cunqueiro Hospital, 3Flow Cytometry Core Facility, 4Cell Culture Core Facility, Biomedical Research Centre (CINBIO), Vigo University, 5Internal Medicine Department, Alvaro Cunqueiro Hospital, Vigo, Spain

Exosomes are extracellular vesicles (EV) ranging from 40 to 100nm implicated not only in cell-cell communication but also involved in numerous physiological processes such as immune regulation. Number and function of EV have been correlated with Multiple Sclerosis (MS). Several independent studies have reported increased levels of EV in MS patients compared to healthy donors.
Platelet derived EV (P-EVs) have been found to participate in a variety of biological and pathological processes including clotting, angiogenesis, inflammation or immunoregulation. Moreover, plasma EV coming from platelets were described as increased in all clinical forms of MS patients; it is believed that a complex interplay of platelets with endothelial and immune cells take part in the pathogenesis of the MS plaque. However, how platelets derived exosomes levels change between relapses and MS remission status and its possible role as inflammation prognostic biomarker has not been characterized yet. Therefore, our aim was to study the prognostic value of P-EVs levels as biomarkers for relapse outcome in relapsing-remitting MS patients
As proof of concept, we analysed 10 Relapse Remitting Multiple Sclerosis patients in both relapse and clinical remission status. Relapse samples were obtained before starting with corticoids treatment. All patients fulfilled the McDonald diagnostic criteria, recruited at the Multiple Sclerosis Unit of Alvaro Cunqueiro Hospital. All subjects gave written informed consent. Exosomes were isolated from plasma and purified following the ExoStep Plasma kit (Immunostep) indications. ExoStep is a immunobead assay for isolation of exosome based on magnetic bead-bound anti-CD63 capture antibodies. Later, specific P-EVs were labelled with fluorescent anti-CD62P. Finally, these complexes were analysed by flow cytometry in a BD Accury C6 . Paired Sample T-test was performed with SPSS 14 software and p-value< 0,05 was considered as statistically significant.
Surprisingly, P-EVs were 2 times increased in relapse samples versus remission samples (p=0,04). P-EVs cold be used as biomarker to differentiate between these two different status. However, more studies are needed to corroborate our results.
Disclosure: The authors declare that they have no competing interests.
This work was supported by Xunta de Galicia ( ED431C 2016/041) the funder had no role in study design, data collection an analysis, decision to submisión or preparation of the abstract.
Araceli Piñeiro-Abuin 'Nothing to disclose'
Ines González-Suarez 'Nothing to disclose'
Mercedes Peleteiro 'Nothing to disclose'
Cesar Sánchez-Franco 'Nothing to disclose'
Marta Aguado-Valcarcel 'Nothing to disclose'
Elena Álvarez 'Nothing to disclose'
Galina Pinzaru 'Nothing to disclose'
Rut Lorenzo-Castro 'Nothing to disclose'
África González-Fernández 'Nothing to disclose'
Jezabel Varadé 'Nothing to disclose'

Abstract: EP1540

Type:

Abstract Category: Pathology and pathogenesis of MS - Biomarkers

A. Piñeiro-Abuin1, I. González-Suarez2, M. Peleteiro3, C. Sánchez-Franco2, M. Aguado-Valcarcel2, E. Álvarez2, G. Pinzaru4, R. Lorenzo-Castro5, Á. González-Fernández1, J. Varadé1

1Immunology Research Group, Biomedical Research Centre (CINBIO), Vigo University, 2Multiple Sclerosis Unit, Neurology Department, Alvaro Cunqueiro Hospital, 3Flow Cytometry Core Facility, 4Cell Culture Core Facility, Biomedical Research Centre (CINBIO), Vigo University, 5Internal Medicine Department, Alvaro Cunqueiro Hospital, Vigo, Spain

Exosomes are extracellular vesicles (EV) ranging from 40 to 100nm implicated not only in cell-cell communication but also involved in numerous physiological processes such as immune regulation. Number and function of EV have been correlated with Multiple Sclerosis (MS). Several independent studies have reported increased levels of EV in MS patients compared to healthy donors.
Platelet derived EV (P-EVs) have been found to participate in a variety of biological and pathological processes including clotting, angiogenesis, inflammation or immunoregulation. Moreover, plasma EV coming from platelets were described as increased in all clinical forms of MS patients; it is believed that a complex interplay of platelets with endothelial and immune cells take part in the pathogenesis of the MS plaque. However, how platelets derived exosomes levels change between relapses and MS remission status and its possible role as inflammation prognostic biomarker has not been characterized yet. Therefore, our aim was to study the prognostic value of P-EVs levels as biomarkers for relapse outcome in relapsing-remitting MS patients
As proof of concept, we analysed 10 Relapse Remitting Multiple Sclerosis patients in both relapse and clinical remission status. Relapse samples were obtained before starting with corticoids treatment. All patients fulfilled the McDonald diagnostic criteria, recruited at the Multiple Sclerosis Unit of Alvaro Cunqueiro Hospital. All subjects gave written informed consent. Exosomes were isolated from plasma and purified following the ExoStep Plasma kit (Immunostep) indications. ExoStep is a immunobead assay for isolation of exosome based on magnetic bead-bound anti-CD63 capture antibodies. Later, specific P-EVs were labelled with fluorescent anti-CD62P. Finally, these complexes were analysed by flow cytometry in a BD Accury C6 . Paired Sample T-test was performed with SPSS 14 software and p-value< 0,05 was considered as statistically significant.
Surprisingly, P-EVs were 2 times increased in relapse samples versus remission samples (p=0,04). P-EVs cold be used as biomarker to differentiate between these two different status. However, more studies are needed to corroborate our results.
Disclosure: The authors declare that they have no competing interests.
This work was supported by Xunta de Galicia ( ED431C 2016/041) the funder had no role in study design, data collection an analysis, decision to submisión or preparation of the abstract.
Araceli Piñeiro-Abuin 'Nothing to disclose'
Ines González-Suarez 'Nothing to disclose'
Mercedes Peleteiro 'Nothing to disclose'
Cesar Sánchez-Franco 'Nothing to disclose'
Marta Aguado-Valcarcel 'Nothing to disclose'
Elena Álvarez 'Nothing to disclose'
Galina Pinzaru 'Nothing to disclose'
Rut Lorenzo-Castro 'Nothing to disclose'
África González-Fernández 'Nothing to disclose'
Jezabel Varadé 'Nothing to disclose'

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies